These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10764166)

  • 1. A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia.
    Pfitzner T; Engert A; Wittor H; Schinköthe T; Oberhäuser F; Schulz H; Diehl V; Barth S
    Leukemia; 2000 Apr; 14(4):754-66. PubMed ID: 10764166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
    Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
    Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
    Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
    Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol.
    Noy A; Verma R; Glenn M; Maslak P; Rahman ZU; Keenan JR; Weiss M; Filippa D; Zelenetz AD
    Blood; 2001 Apr; 97(7):1929-36. PubMed ID: 11264154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular analysis of rearranged VH genes during B cell chronic lymphocytic leukemia: intraclonal stability is frequent but not constant.
    Korganow AS; Martin T; Weber JC; Lioure B; Lutz P; Knapp AM; Pasquali JL
    Leuk Lymphoma; 1994 Jun; 14(1-2):55-69. PubMed ID: 7920229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of immunoglobulin gene rearrangement of B cell non-Hodgkin's lymphomas and leukemias in fresh, unfixed and formalin-fixed, paraffin-embedded tissue by polymerase chain reaction.
    Inghirami G; Szabolcs MJ; Yee HT; Corradini P; Cesarman E; Knowles DM
    Lab Invest; 1993 Jun; 68(6):746-57. PubMed ID: 8515660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias.
    Linke B; Pyttlich J; Tiemann M; Suttorp M; Parwaresch R; Hiddemann W; Kneba M
    Leukemia; 1995 May; 9(5):840-7. PubMed ID: 7769847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma.
    Andersen NS; Donovan JW; Zuckerman A; Pedersen L; Geisler C; Gribben JG
    Exp Hematol; 2002 Jul; 30(7):703-10. PubMed ID: 12135667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation.
    Provan D; Bartlett-Pandite L; Zwicky C; Neuberg D; Maddocks A; Corradini P; Soiffer R; Ritz J; Nadler LM; Gribben JG
    Blood; 1996 Sep; 88(6):2228-35. PubMed ID: 8822943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia.
    Peková S; Marková J; Pajer P; Dvorák M; Cetkovský P; Schwarz J
    Mol Diagn; 2005; 9(1):23-34. PubMed ID: 16035732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of residual disease in non-Hodgkin's lymphomas by quantitative PCR (preliminary report).
    Slavícková A; Ullmannová V; Benesová E; Klener P
    Folia Biol (Praha); 1999; 45(5):179-83. PubMed ID: 10730886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescent polymerase chain reaction and capillary electrophoresis for IgH rearrangement and minimal residual disease evaluation in multiple myeloma.
    Novella E; Giaretta I; Elice F; Madeo D; Piccin A; Castaman G; Rodeghiero F
    Haematologica; 2002 Nov; 87(11):1157-64. PubMed ID: 12414345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The detection of minimal residual disease in patients with chronic B-cell lymphatic leukemia using patient-specified polymerase chain reaction].
    Sidorova IuV; Sorokina TV; Biderman BV; Nikulina EE; Kisilichina DG; Naumova EV; Pochtar' ME; Lugovskaia SA; Ivanova VL; Kovaleva LG; Ptushkin VV; Nikitin EA; Sudarikov AB
    Klin Lab Diagn; 2011 Dec; (12):22-4, 33-5. PubMed ID: 22416427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis of quantitation standards for nested competitive PCR for the determination of minimal residual disease in B-lineage acute lymphoblastic leukaemia.
    Martin G; Mairs RJ
    Leuk Res; 1997 Sep; 21(9):807-9. PubMed ID: 9393594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of IgVH mutational status on the induction of apoptosis by rituximab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: evidence from a clinical phase I/II trial.
    Tinhofer I; Steurer M; Leitinger G; Rumpold H; Egle A; Erdel M; Greil R
    Haematologica; 2006 Sep; 91(9):1291-3. PubMed ID: 16956841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic lymphocytic leukemia: current and emerging treatment approaches.
    Kay NE; Rai KR; O'Brien S
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
    Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
    Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements.
    Vuillier F; Claisse JF; Vandenvelde C; Travade P; Magnac C; Chevret S; Desablens B; Binet JL; Dighiero G
    Leuk Lymphoma; 1992 Jun; 7(3):195-204. PubMed ID: 1282428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved.
    Ouspenskaia MV; Johnston DA; Roberts WM; Estrov Z; Zipf TF
    Leukemia; 1995 Feb; 9(2):321-8. PubMed ID: 7869771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells.
    Hashimoto S; Dono M; Wakai M; Allen SL; Lichtman SM; Schulman P; Vinciguerra VP; Ferrarini M; Silver J; Chiorazzi N
    J Exp Med; 1995 Apr; 181(4):1507-17. PubMed ID: 7535340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.